Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another form of the disease. The company said Tuesday that Myqorzo ...
May 5, 2026 07:30 AM EDT R&DPharma Cytokinetics succeeds where Bristol Myers failed in heart muscle disease Elizabeth Cairns Senior biopharma journalist Cytokinetics’ pill for a heart muscle disorder called hypertrophic cardiomyopathy could see its addressable market double after it succeeded in a pivotal trial for another … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that